Press Releases

Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body’s overwhelming immune response to an infection, which can lead to tissue…

Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress’ SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected of sepsis. DRIVe (Division of…

Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’ from both the U.S. Patent…

The allowance complements the Company’s growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, “Validating biomarker measurement,” which relates to methods…

SEATTLE, July 10, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company’s Executive Team as Vice President of Regulatory Affairs and Quality. “Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences industry,” Rolland D. Carlson, PhD, President…

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine, of data demonstrating the ability…

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International…

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation…

Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker blood signature to discriminate viral…